4-(3,4-Dihydro-2,2-dioxo-1H-2,1,3-benzothiadiazin-3-yl)-piperidine | 205058-98-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(3,4-Dihydro-2,2-dioxo-1H-2,1,3-benzothiadiazin-3-yl)-piperidine
• 英文别名: 3,4-dihydro-2,2-dioxido-3-(4-piperidinyl)-2,1,3-benzothiadiazine；3-Piperidin-4-yl-3,4-dihydro-1H-benzo[1,2,6]thiadiazine-2,2-dioxide；3,4-dihydro-2,2-dioxido-3-(4-piperidinyl)-2,1,3-benzothiadiazin；3-(piperidin-4-yl)-3,4-dihydro-1H-benzo[c][1,2,6]thiadiazine 2,2-dioxide；3-piperidin-4-yl-1,4-dihydro-2λ6,1,3-benzothiadiazine 2,2-dioxide
• CAS: 205058-98-6
• 化学式: C₁₂H₁₇N₃O₂S
• 分子量: 267.352
• InChiKey: NAABSTTTWHTWQQ-UHFFFAOYSA-N

物化性质

• 沸点：
  431.2±55.0 °C(Predicted)
• 密度：
  1.297±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  69.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-氯-6,7-二甲氧基喹唑啉 、 4-(3,4-Dihydro-2,2-dioxo-1H-2,1,3-benzothiadiazin-3-yl)-piperidine 生成 3-[1-(6,7-Dimethoxyquinazolin-4-yl)piperidin-4-yl]-1,4-dihydro-2lambda6,1,3-benzothiadiazine 2,2-dioxide
  参考文献：
  名称：

  NOMOTO, YUJI;OBASE, HIROYUKI;TAKAI, HARUKI;HIRATA, TADASHI;TERANISHI, MAS+, CHEM. AND PHARM. BULL., 38,(1990) N, C. 1591-1595

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氨基-1-苄基哌啶 在 palladium on activated charcoal 吡啶 、 甲醇 、 sodium tetrahydroborate 、 氢气 、 磺酰胺 作用下， 以 乙醇 为溶剂， 生成 4-(3,4-Dihydro-2,2-dioxo-1H-2,1,3-benzothiadiazin-3-yl)-piperidine
  参考文献：
  名称：

  [EN] DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS
  [FR] INDUCTEURS, À BASE DE DIPHÉNYLBUTYLPIPÉRIDINE, DE L'AUTOPHAGIE

  摘要：

  公开号：

  WO2011143444A3

文献信息

• Modified aminoacids, pharmaceuticals containing these compounds and method for their production
  申请人：Dr. Karl Thomae GmbH

  公开号：US06344449B1

  公开（公告）日：2002-02-05

  The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4 and R11 are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

  本发明涉及一般式的改性氨基酸 其中 A、Z、X、n、m、R、R2、R3、R4和R11的定义如权利要求1至5中所述，它们的互变异构体、对映异构体、立体异构体、它们的混合物及其盐，特别是其与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的药物组合物，其用途以及制备它们的过程，以及它们在抗体的生产和纯化中的用途以及在RIA和ELISA测定中作为标记化合物以及在神经递质研究中作为诊断或分析辅助工具的用途。
• Calcitonin gene related peptide receptor antagonists
  申请人：——

  公开号：US20040204397A1

  公开（公告）日：2004-10-14

  The present invention relates to compounds of Formula (I) 1 as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

  本发明涉及式（I）的化合物作为降钙素基因相关肽受体（“CGRP受体”）拮抗剂，包括它们的药物组合物，用于识别它们的方法，使用它们进行治疗的方法，以及它们在治疗神经源性血管舒张、神经源性炎症、偏头痛和其他头痛、热损伤、循环休克、与绝经相关的潮红、气道炎症性疾病（如哮喘和慢性阻塞性肺病（COPD））以及其他可以通过拮抗CGRP受体来治疗的疾病的治疗中的用途。
• Modified amino acids, pharmaceuticals containing these compounds and method for their production
  申请人：——

  公开号：US20010036946A1

  公开（公告）日：2001-11-01

  The present invention relates to modified amino acids of general formula 1 wherein A, Z, X, n, m, R, R 2 , R 3 , R 4 and R 11 are defined as in claims 1 to 5 , their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

  本发明涉及一般式1的改良氨基酸，其中A、Z、X、n、m、R、R2、R3、R4和R11如权利要求1至5中所定义，它们的互变异构体、对映异构体、混合物及其盐，特别是其与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的药物组合物，其用途以及用于制备它们的过程，以及它们在抗体的生产和纯化中的用途，以及在RIA和ELISA测定中作为标记化合物以及在神经递质研究中作为诊断或分析辅助工具的用途。
• CGRP receptor antagonists
  申请人：Gutierrez Corey

  公开号：US20080004261A1

  公开（公告）日：2008-01-03

  The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.

  本发明涉及CGRP受体拮抗剂，其药物组成物，以及用于治疗CGRP受体介导的疾病和症状的方法。
• Studies on cardiotonic agents. II. Synthesis of novel phthalazine and 1,2,3-benzotriazine derivatives.
  作者：Yuji NOMOTO、Hiroyuki OBASE、Haruki TAKAI、Masayuki TERANISHI、Joji NAKAMURA、Kazuhiro KUBO

  DOI：10.1248/cpb.38.2179

  日期：——

  A series of phthalazine and 1, 2, 3-benzotriazine derivatives which have heterocyclylpiperidino groups was synthesized and tested for cardiotonic activity in anesthetized dogs. Several 6, 7-dimethoxyphthalazine derivatives showed relatively potent cardiotonic activity comparable to that of amrinone.

  合成了一系列具有杂环基哌啶基的二氮杂萘和1,2,3-苯并三嗪衍生物，并测试了麻醉犬的强心活性。几种6, 7-二甲氧基酞嗪衍生物显示出与氨力农相当的相对有效的强心活性。